Defactinib
As of the edition of 20 October 2026, Defactinib is a small molecule: marketed, first approved in 2025 (US); acts on PTK2 and PTK2B; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Avmapki Fakzynja Co-Pack (copackaged)
- First approved
- 8 May 2025 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Verastem
- Registered trials
- 40, 6 stopped early
- Disease areas
- Cancer; Hormones; Digestive system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 12 | 5 | 4 | 3 |
| Phase 2 | 27 | 3 | 20 | 3 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 40 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Verastem | Lead sponsor of trials | 2008 to now |